New vaccine aims to keep ovarian cancer at bay

NCT ID NCT06639074

First seen Nov 01, 2025 · Last updated May 11, 2026 · Updated 23 times

Summary

This study tests a vaccine made from a patient's own white blood cells, designed to train the immune system to attack ovarian cancer cells. It is for people with advanced stage III or IV ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if the vaccine can delay or prevent the cancer from coming back compared to a placebo.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OVARIAN CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mayo Clinic in Arizona

    RECRUITING

    Scottsdale, Arizona, 85259, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Mayo Clinic in Florida

    RECRUITING

    Jacksonville, Florida, 32224-9980, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Mayo Clinic in Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.